Cidara Therapeutics (CDTX) Misses Q2 EPS by 1c

Cidara Therapeutics (NASDAQ: CDTX) reported Q2 EPS of ($0.14), $0.01 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $7.61 million versus the consensus estimate of $11.55 million.

For earnings history and earnings-related data on Cidara Therapeutics (CDTX) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
• Investing.com’s stocks of the week